A multicenter phase II trial of ramucirumab plus irinotecan for early recurrence of gastric cancer during or after adjuvant chemotherapy with docetaxel plus S-1 therapy: the RAMIEL trial (OGSG1901)
Multizentrische Phase-II-Studie zu Ramucirumab plus Irinotecan bei früher Rezidivierung von Magenkarzinom während oder nach adjuvanter Docetaxel-plus-S-1-Therapie: RAMIEL-Studie (OGSG1901)
Gastric Cancer · 2026-11 · 29 (6) · 1349-1359
DOI: 10.1007/s10120-026-01799-8 ↗Auf einen Blick
Bei 39 Patient:innen mit früher Rezidivierung eines Magenkarzinoms zeigte Ramucirumab plus Irinotecan ein medianes Gesamtüberleben von 15,9 Monaten und eine ORR von 38,5 %.
Fragestellung
Wie wirksam und sicher ist Ramucirumab plus Irinotecan bei früher Rezidivierung von Magenkarzinom während oder innerhalb von 6 Monaten nach adjuvanter DS-Therapie?
Methode
Prospektive, offene, multizentrische Phase-II-Studie an 25 Zentren in Japan; Ramucirumab 8 mg/kg plus Irinotecan 150 mg/m2 alle 2 Wochen.
Ergebnisse
43 eingeschlossen, 39 analysiert. Medianes OS 15,9 Monate (95 %-KI 8,8–42,0; p = 0,003), medianes PFS 5,5 Monate (95 %-KI 3,9–8,1), ORR 38,5 %.
Schlussfolgerung der Autor:innen
Ramucirumab plus Irinotecan zeigte bei früher Rezidivierung nach adjuvanter DS-Therapie eine vielversprechende Wirksamkeit und vertretbare Toxizität.
Kernaussagen
- Medianes OS: 15,9 Monate
- Medianes PFS: 5,5 Monate; ORR: 38,5 %
- Unerwünschte Ereignisse Grad ≥ 3: Neutropenie und Hypertonie je 25,6 %
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Gastric Cancer, online erschienen am 16.09.2026. Verfasst von Toshifumi Yamaguchi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University Hospital, 2-7, Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The University of Tokyo.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
There is currently no established chemotherapy regimen for early recurrence of pathological stage III gastric cancer (GC) following adjuvant chemotherapy with docetaxel plus S-1 (DS) after D2 gastrectomy. We aimed to evaluate the efficacy and safety of ramucirumab plus irinotecan in patients with GC who experienced early recurrence during or within 6 months after DS adjuvant chemotherapy.
Methods
This prospective, open-label, multicenter phase II trial enrolled eligible patients treated at 25 centers of the Osaka Gastrointestinal Cancer Chemotherapy Study Group in Japan. Patients received ramucirumab (8 mg/kg) and irinotecan (150 mg/m 2 ) every 2 weeks. The primary endpoint was overall survival (OS), and secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and safety. The sample size was set at 40 based on a threshold median OS of 7 months and an expected median OS of 11 months, with a one-sided alpha error of 0.05 and a power of 0.80.
Results
Between November 2019 and July 2023, 43 patients were enrolled, and 39 were included in the analysis after excluding three ineligible patients and one who did not initiate protocol treatment. The median OS was 15.9 months (95% CI: 8.8–42.0; p = 0.003). The median PFS was 5.5 months (95% CI: 3.9–8.1), and the ORR was 38.5%. Grade ≥ 3 adverse events, including neutropenia (25.6%) and hypertension (25.6%), were observed in more than 20% of patients.
Conclusion
Ramucirumab plus irinotecan demonstrated promising efficacy and manageable toxicity in patients with early recurrence of GC following adjuvant DS therapy.
Trial registration
This study was prospectively registered in the Japan Registry of Clinical Trials (jRCTs05119071, October 6, 2019, https://jrct.niph.go.jp/latest-detail/jRCTs051190071 ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University Hospital, 2-7, Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan.
- Department of Surgery, Sakai City Medical Center, 1-1-1 Ebaraji-Cho, Sakai-Shi, Osaka, 272-1199, Japan.
- Department of Gastroenterological Surgery, Osaka Rosai Hospital, 1179-3 Nakasonecho, Kita-Ku, Sakai-Shi, Osaka, 591-8025, Japan.
- Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
- Department of Surgery, Kansai Rosai Hospital, 3-1-69 Inabaso, Amagasaki, Hyogo, 660-8511, Japan.
- Department of Surgery, Osaka General Medical Center, 3-1-56 Bandaihigashi, Sumiyoshi-Ku, Osaka City, Osaka, 558-8558, Japan.
Förderung
- The University of Tokyo
Zitieren
APA
Yamaguchi, T., Kawabata, R., Akamaru, Y., Hirano, H., Sugimura, K., Miyazaki, Y., Kakeji, Y., Kito, Y., Nomura, T., Kawakami, T., Tanemura, M., Takeno, A., Okuda, H., Matsushima, T., Shimokawa, T., Kurokawa, Y., Endo, S., Boku, N., & Satoh, T. (2026). A multicenter phase II trial of ramucirumab plus irinotecan for early recurrence of gastric cancer during or after adjuvant chemotherapy with docetaxel plus S-1 therapy: the RAMIEL trial (OGSG1901). Gastric Cancer, 29(6), 1349-1359. https://doi.org/10.1007/s10120-026-01799-8
Vancouver
Yamaguchi T, Kawabata R, Akamaru Y, Hirano H, Sugimura K, Miyazaki Y, et al. A multicenter phase II trial of ramucirumab plus irinotecan for early recurrence of gastric cancer during or after adjuvant chemotherapy with docetaxel plus S-1 therapy: the RAMIEL trial (OGSG1901). Gastric Cancer. 2026;29(6):1349-1359. doi:10.1007/s10120-026-01799-8
BibTeX
@article{Yamaguchi2026,
author = {Yamaguchi, Toshifumi and Kawabata, Ryohei and Akamaru, Yusuke and Hirano, Hidekazu and Sugimura, Keijiro and Miyazaki, Yasuhiro and Kakeji, Yoshihiro and Kito, Yosuke and Nomura, Takashi and Kawakami, Takeshi and Tanemura, Masahiro and Takeno, Atsushi and Okuda, Hiroyuki and Matsushima, Tomohiro and Shimokawa, Toshio and Kurokawa, Yukinori and Endo, Shunji and Boku, Narikazu and Satoh, Taroh},
title = {A multicenter phase II trial of ramucirumab plus irinotecan for early recurrence of gastric cancer during or after adjuvant chemotherapy with docetaxel plus S-1 therapy: the RAMIEL trial (OGSG1901)},
journal = {Gastric Cancer},
year = {2026},
volume = {29},
number = {6},
pages = {1349--1359},
doi = {10.1007/s10120-026-01799-8}
}
EUVIMED